Attendee search 

Are you seeking to develop your R&D skills, enhance your innovation potential and increase your business opportunities ? Check how Medicen Paris Region can help you.

iGlide and the Cornea range bring innovative lamellar conservation and transportation solutions that make the corneal graft easier, quicker and more flexible. The cornea is trephined and pre-cut in the eye bank. Lamellar membrane is placed in the iGlide, conserved in the medium and sent to the physician.

iGlide saves time during surgeries, and isn

1/ Eye banks 2/ Other tissue brokers 3/ Surgeons 4/ Hospitals - GPO

1/ non invasive 2/ inexpensive 3/ no learning curve for surgeon 4/ Best quality for the eye banks and physicians

Our unique technology combines visco elastic shock absorbers with rigid components in one device to restore the anatomical functions. Our first product 

B Dyn relieves pressure on the inter vertebral disc as well as the articular facets and by controlling motion, preserves the intervertebral disc and the articular facets from final fusion. For the patients the outcomes evaluated 2 years after the surgery are superior to the standard technic of fusion.

Lumbar Spine Degenerative Market

Superior clinical outcomes 

Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy evaluation and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission.

Porsolt provides physiopathological models in multiples species, customized procedures, and tailored solutions, (including in vitro assays and drug formulation analysis and bioanalytical services), for psychiatric and neurological disorders, pain, cardiac and vascular diseases, metabolic and eating disorders, and dermatology.

Pharmaceutical companies / Biotechs / Fondations / Academia

Science-based / GLP compliance / tailored solutions / flexibility

AMABIOTICS analyse metabolic interplays between humans and its microbial associated communities. AMABIOTICS discovered novel actions of natural chemical compounds provided by the microbiome that the host cannot synthesize by itself. Our pipeline of products candidates is led by AMA-101 as a potential first-in-class therapy for Parkinson disease.

We address the major issue of preventing mitochondrial dysfunction

1 - Neurodegenerative disease / 2 - Obesity / 3 - Tissue regeneration

Original and specific mode of action / Crosses the blood-brain barrier / Co-evolution with our organism (low risk of adverse side effect).

Bio-Modeling Systems is the world’s first Mechanisms-Based medicine company that changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data to generate validated & directly exploitable first in class heuristic non-mathematical mechanistic CADI™* models. 

Created in 2004, profitable since 2006, thanks to our recurrent clients, we confirmed with our partners CADI™ Discovery capability to generate outstanding value through:

·         Dual business model: Contractual or Collaborative R&D programs.

·         External valorization of our collaborative R&D programs through out-licensing or spin-off.

·         Outstanding internal pipeline of programs ready for collaborations, and

·         Already a world's first in neurodegenerative diseases, 1 therapeutic spin-off, 1 exclusive out-license, 4 issued patents, 10 publications (for all details, visit BMSystems website).

We propose to Research, Discovery, Development people, considering that 90-95% failure rate is unacceptable but not a fatality, robust alternative solutions for their critical issues and decisions to make. 

You have a question; we may have the ability to generate the answer through one of our 6 BMSystems’ solutions to critical & high impact issues.

1.       GO-NO GO decision before product acquisition or for portfolio risk analysis.

2.       GO-NO GO decision before next development phase.

3.       R&D program Rescue for a program facing critical issues during its lifetime.

4.       External R&D “B plan” program when the “A plan” cannot be rescued.

5.       Exploratory Discovery program to generate novel causal mechanisms concepts.

6.       Novel Hypotheses for therapeutic and/or diagnostic solutions generation.

We warmly invite you to download our  7 pages management summary,  our Short corporate Presentation or our Full Presentation with all non-confidential details of our 10 POCs.

"Correct understanding of life mechanisms makes novel integrated diagnostics, therapies & preventive solutions discovery smarter, faster & cheaper for healthcare, diagnostic, health technologies, nutrition, and cosmetics!" 

As a part of our advanced concept and system combining mobile hardware with sensor, smarts of software engines capabilities and personalized dashboard; our exclusive & patented BIA measurement & analysis offers a direct valuation of body composition, hydration and nutrition status at one glance.

Our unique 

Health/weight management/Sport/Seniors/

Connected Device & cloud based engine & storage technology/ The only one in this range of product to deliver instantly full body composition analysis/ Accurate & reliable / Highly personalizable and flexible

Bertin Pharma recently integrates one of the most outstanding GMP facilities in Europe specifically dedicated to the Pharmaceutical development of OTC. A large panel of original Drug Delivery Systems particularly suitable to fit the OTC needs with optimized sensorial attributes are available. Among them Dualtab

DUALTAB

Ethics (NCEs & Biologics), OTC, Generic plus 

Quick local symptoms relief Dual action quick and long lasting Product design makes dual action visible for patients Robust manufacturing process and low industrial cost price